ArticleJournal of virology2007
Structure-based identification of a major neutralizing site in an adenovirus hexon.
Article in Journal of virology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 112 citations in OpenAlex.
- Development and clinical application of a TaqMan-based real-time quantitative PCR assay for rapid detection of goose adenovirus type 4.Frontiers in microbiology · 2026Article
- The seroprevalence of adenoviruses since 2000Emerging microbes & infections · 2025Review
- Molecular characterization and evolutionary analysis of human adenovirus type 55, related to febrile respiratory illness in the South Korean military.Virus genes · 2025Article
- Molecular characteristics of human adenovirus isolated from the 2024 influenza-like illness outbreaks in Suzhou City, China.Virology journal · 2025Article
- Adenovirus-Specific T Cells in Adults Are Frequent, Cross-Reactive to Common Childhood Adenovirus Infections and Boosted by Adenovirus-Vectored Vaccines.Journal of medical virology · 2025Article
- A recombinant virus-like particle vaccine against adenovirus-7 induces a potent humoral response.NPJ vaccines · 2023Article
- Article
- Icosahedral gold nanoparticles decorated with hexon protein: a surrogate for adenovirus serotype 5.Analytical and bioanalytical chemistry · 2023Article
- Significance of Preexisting Vector Immunity and Activation of Innate Responses for Adenoviral Vector-Based Therapy.Viruses · 2022Review
- Hsp70 Inhibits the Replication of Fowl Adenovirus Serotype 4 by Suppressing Viral Hexon with the Assistance of DnaJC7.Journal of virology · 2022Article
- New p35 (H3L) Epitope Involved in Vaccinia Virus Neutralization and Its Deimmunization.Viruses · 2022Article
- Identification of Recombinant Chimpanzee Adenovirus C68 Degradation Products Detected by AEX-HPLC.Frontiers in bioengineering and biotechnology · 2022Article
- Epidemiological and molecular analysis of circulating fowl adenoviruses and emerging of serotypes 1, 3, and 8b in Egypt.Heliyon · 2021Article
- Construction and Characterization of a Novel Recombinant Attenuated and Replication-Deficient Candidate Human Adenovirus Type 3 Vaccine: "Adenovirus Vaccine Within an Adenovirus Vector".Virologica Sinica · 2021Article
- Immunological Study of Reconstructed Common Ancestral Sequence of Adenovirus Hexon Protein.Frontiers in microbiology · 2021Article
- Design and Engineering of Deimmunized Vaccinia Viral Vectors.Biomedicines · 2020Review
- Bioinformatics analysis reveals four major hexon variants of human adenovirus type-3 (HAdV-3) as the potential strains for development of vaccine and siRNA-based therapeutics against HAdV-3 respiratory infections.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2020Article
- Immunology of Adenoviral Vectors in Cancer Therapy.Molecular therapy. Methods & clinical development · 2019Review
- Molecular evolution of human adenovirus type 16 through multiple recombination events.Virus genes · 2019Article
- Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy.Nature communications · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
Virus-specific neutralizing antibodies present an obstacle to the effective use of adenovirus vectors for gene therapy and vaccination. The specific sites recognized by neutralizing antibodies have not been identified for any adenovirus, but they have been proposed to reside within the hexon, in small regions of the molecule that are exposed on the capsid surface and possess sequences that vary among serotypes. We have mapped the epitopes recognized by a panel of seven hexon-specific monoclonal antibodies that neutralize the chimpanzee adenovirus 68 (AdC68). Surface plasmon resonance experiments revealed that the antibodies compete for a single hexon binding site, and experiments with synthetic peptides indicated that this site resides within just one small surface loop. Mutations within this loop (but not in other surface loops) permitted virus to escape neutralization by all seven monoclonal antibodies and to resist neutralization by polyclonal antisera obtained from animals immunized against AdC68. These results indicate that a single small surface loop defines a major neutralization site for AdC68 hexon.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.